Artwork

ืชื•ื›ืŸ ืžืกื•ืคืง ืขืœ ื™ื“ื™ Flot.bio. ื›ืœ ืชื•ื›ืŸ ื”ืคื•ื“ืงืืกื˜ื™ื ื›ื•ืœืœ ืคืจืงื™ื, ื’ืจืคื™ืงื” ื•ืชื™ืื•ืจื™ ืคื•ื“ืงืืกื˜ื™ื ืžื•ืขืœื™ื ื•ืžืกื•ืคืงื™ื ื™ืฉื™ืจื•ืช ืขืœ ื™ื“ื™ Flot.bio ืื• ืฉื•ืชืฃ ืคืœื˜ืคื•ืจืžืช ื”ืคื•ื“ืงืืกื˜ ืฉืœื”ื. ืื ืืชื” ืžืืžื™ืŸ ืฉืžื™ืฉื”ื• ืžืฉืชืžืฉ ื‘ื™ืฆื™ืจื” ืฉืœืš ื”ืžื•ื’ื ืช ื‘ื–ื›ื•ื™ื•ืช ื™ื•ืฆืจื™ื ืœืœื ืจืฉื•ืชืš, ืืชื” ื™ื›ื•ืœ ืœืขืงื•ื‘ ืื—ืจ ื”ืชื”ืœื™ืš ื”ืžืชื•ืืจ ื›ืืŸ https://he.player.fm/legal.
Player FM - ืืคืœื™ืงืฆื™ื™ืช ืคื•ื“ืงืืกื˜
ื”ืชื—ืœ ื‘ืžืฆื‘ ืœื ืžืงื•ื•ืŸ ืขื ื”ืืคืœื™ืงืฆื™ื” Player FM !

Bahija Jallal, Immunocore ๐Ÿ‡ฌ๐Ÿ‡ง | Commercial, Diversity, and AI | E14

1:15:45
 
ืฉืชืคื•
 

Manage episode 409010244 series 3470295
ืชื•ื›ืŸ ืžืกื•ืคืง ืขืœ ื™ื“ื™ Flot.bio. ื›ืœ ืชื•ื›ืŸ ื”ืคื•ื“ืงืืกื˜ื™ื ื›ื•ืœืœ ืคืจืงื™ื, ื’ืจืคื™ืงื” ื•ืชื™ืื•ืจื™ ืคื•ื“ืงืืกื˜ื™ื ืžื•ืขืœื™ื ื•ืžืกื•ืคืงื™ื ื™ืฉื™ืจื•ืช ืขืœ ื™ื“ื™ Flot.bio ืื• ืฉื•ืชืฃ ืคืœื˜ืคื•ืจืžืช ื”ืคื•ื“ืงืืกื˜ ืฉืœื”ื. ืื ืืชื” ืžืืžื™ืŸ ืฉืžื™ืฉื”ื• ืžืฉืชืžืฉ ื‘ื™ืฆื™ืจื” ืฉืœืš ื”ืžื•ื’ื ืช ื‘ื–ื›ื•ื™ื•ืช ื™ื•ืฆืจื™ื ืœืœื ืจืฉื•ืชืš, ืืชื” ื™ื›ื•ืœ ืœืขืงื•ื‘ ืื—ืจ ื”ืชื”ืœื™ืš ื”ืžืชื•ืืจ ื›ืืŸ https://he.player.fm/legal.

Weโ€™re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering. ๐Ÿ’Ž ABOUT THE SPEAKER Iโ€™ve โ€œknownโ€ Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bioengineering in France. At that time, she was head of MedImmune and SVP R&D at AstraZeneca. Now as the CEO of Immunocore, with their pioneering T cell receptor platform, she has helped to bring incredible treatments for cancer patients to market. ๐Ÿ”— LINKS MENTIONED - Bahija on the Breakthrough Labs podcast - https://open.spotify.com/episode/2X4xedUdJid9GeioRSkCrP?si=39d8c7511aab443f - Immatics builds on its PRAME Success (and competes with Immunocore) - [OncologyPipeline.com](https://www.oncologypipeline.com/apexonco/immatics-builds-its-prame-success) ๐Ÿ“œ TRANSCRIPT Read the full transcript here: ๐Ÿซถ FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio ๐ŸŽ™๏ธ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. โญ๏ธ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! ๐Ÿ™ LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. โฐ TIMESTAMPS

[00:00:00] Intro

[00:00:34] Welcome

[00:01:46] Immunocoreโ€™s life-changing cancer drug

[00:07:40] Commercializing Immunocore

[00:13:46] Explaining the TCR technology

[00:20:40] Targeting tumors with PRAME

[00:23:26] Immunocore now and then

[00:35:37] Why Bahija chose Immunocore

[00:40:22] Top lessons from Bahija Jallal

[00:45:48] How is risk appetite connected to innovation?

[00:49:10] Diversity in biotech

[01:00:59] Biological innovation

[01:05:49] AI in protein engineering optimization

[01:14:42] Thanks for listening

  continue reading

20 ืคืจืงื™ื

Artwork
iconืฉืชืคื•
 
Manage episode 409010244 series 3470295
ืชื•ื›ืŸ ืžืกื•ืคืง ืขืœ ื™ื“ื™ Flot.bio. ื›ืœ ืชื•ื›ืŸ ื”ืคื•ื“ืงืืกื˜ื™ื ื›ื•ืœืœ ืคืจืงื™ื, ื’ืจืคื™ืงื” ื•ืชื™ืื•ืจื™ ืคื•ื“ืงืืกื˜ื™ื ืžื•ืขืœื™ื ื•ืžืกื•ืคืงื™ื ื™ืฉื™ืจื•ืช ืขืœ ื™ื“ื™ Flot.bio ืื• ืฉื•ืชืฃ ืคืœื˜ืคื•ืจืžืช ื”ืคื•ื“ืงืืกื˜ ืฉืœื”ื. ืื ืืชื” ืžืืžื™ืŸ ืฉืžื™ืฉื”ื• ืžืฉืชืžืฉ ื‘ื™ืฆื™ืจื” ืฉืœืš ื”ืžื•ื’ื ืช ื‘ื–ื›ื•ื™ื•ืช ื™ื•ืฆืจื™ื ืœืœื ืจืฉื•ืชืš, ืืชื” ื™ื›ื•ืœ ืœืขืงื•ื‘ ืื—ืจ ื”ืชื”ืœื™ืš ื”ืžืชื•ืืจ ื›ืืŸ https://he.player.fm/legal.

Weโ€™re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering. ๐Ÿ’Ž ABOUT THE SPEAKER Iโ€™ve โ€œknownโ€ Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bioengineering in France. At that time, she was head of MedImmune and SVP R&D at AstraZeneca. Now as the CEO of Immunocore, with their pioneering T cell receptor platform, she has helped to bring incredible treatments for cancer patients to market. ๐Ÿ”— LINKS MENTIONED - Bahija on the Breakthrough Labs podcast - https://open.spotify.com/episode/2X4xedUdJid9GeioRSkCrP?si=39d8c7511aab443f - Immatics builds on its PRAME Success (and competes with Immunocore) - [OncologyPipeline.com](https://www.oncologypipeline.com/apexonco/immatics-builds-its-prame-success) ๐Ÿ“œ TRANSCRIPT Read the full transcript here: ๐Ÿซถ FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio ๐ŸŽ™๏ธ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. โญ๏ธ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! ๐Ÿ™ LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. โฐ TIMESTAMPS

[00:00:00] Intro

[00:00:34] Welcome

[00:01:46] Immunocoreโ€™s life-changing cancer drug

[00:07:40] Commercializing Immunocore

[00:13:46] Explaining the TCR technology

[00:20:40] Targeting tumors with PRAME

[00:23:26] Immunocore now and then

[00:35:37] Why Bahija chose Immunocore

[00:40:22] Top lessons from Bahija Jallal

[00:45:48] How is risk appetite connected to innovation?

[00:49:10] Diversity in biotech

[01:00:59] Biological innovation

[01:05:49] AI in protein engineering optimization

[01:14:42] Thanks for listening

  continue reading

20 ืคืจืงื™ื

ะฃัั– ะตะฟั–ะทะพะดะธ

×
 
Loading …

ื‘ืจื•ื›ื™ื ื”ื‘ืื™ื ืืœ Player FM!

Player FM ืกื•ืจืง ืืช ื”ืื™ื ื˜ืจื ื˜ ืขื‘ื•ืจ ืคื•ื“ืงืืกื˜ื™ื ื‘ืื™ื›ื•ืช ื’ื‘ื•ื”ื” ื‘ืฉื‘ื™ืœื›ื ื›ื“ื™ ืฉืชื”ื ื• ืžื”ื ื›ืจื’ืข. ื–ื” ื™ื™ืฉื•ื ื”ืคื•ื“ืงืืกื˜ ื”ื˜ื•ื‘ ื‘ื™ื•ืชืจ ื•ื”ื•ื ืขื•ื‘ื“ ืขืœ ืื ื“ืจื•ืื™ื“, iPhone ื•ืื™ื ื˜ืจื ื˜. ื”ื™ืจืฉืžื• ืœืกื ื›ืจื•ืŸ ืžื ื•ื™ื™ื ื‘ืžื›ืฉื™ืจื™ื ืฉื•ื ื™ื.

 

ืžื“ืจื™ืš ืขื–ืจ ืžื”ื™ืจ

ืคื•ื“ืงืืกื˜ื™ื ืžื•ื‘ื™ืœื™ื